BDR Pharma launches patient-friendly prostrate cancer therapy

BDR Pharma launches BDENZA (Enzalutamide), the world's first oral solution for prostate cancer management. BDENZA is priced at Rs 27,000 for 150mL, offering reduced dosing frequency, toxicity, and side effects compared to existing oral formulations. The innovative formulation improves patient compliance with its palatable...